Education
About Us
Working with TipRanks
Follow Us
Sunshine Biopharma (SBFM)
NASDAQ:SBFM
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$1.13 - $3.90
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$5.69M
Enterprise Value-$2.76M
Total Cash (Recent Filing)$9.31M
Total Debt (Recent Filing)$854.76K
Price to Earnings (P/E)―
Beta1.81
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding4,905,945
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.09
Price to Sales (P/S)0.06
P/FCF Ratio-0.14
Enterprise Value/Market Cap-0.49
Enterprise Value/Revenue-0.07
Enterprise Value/Gross Profit-0.22
Enterprise Value/Ebitda0.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$50.00M
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureVery low leverage provides durable financial flexibility for a biotech with long, capital-intensive development cycles. Low debt reduces fixed interest obligations, lowering bankruptcy risk and extending runway, which supports R&D continuity and partnership negotiations over months.
Stable Gross MarginA consistent ~33% gross margin indicates structural pricing power or controllable COGS on the company’s products and formulations. This margin buffer helps absorb SG&A and R&D spend, supporting sustainable investment in pipelines and improving odds of progressing candidates without immediate margin erosion.
Partnership- And Licensing-Focused ModelA business model centered on partnerships and licensing reduces sole commercial execution risk and can provide non-dilutive funding, regulatory expertise, and market access. Strategically aligned collaborators can accelerate commercialization and de-risk late-stage investment needs over the medium term.
Bears Say
Weak Cash Flow GenerationSustained negative operating and free cash flows constrain the company’s ability to fund trials and operations internally, increasing reliance on external financing or partnerships. Over several months this raises dilution risk, limits strategic optionality, and can slow development timelines if cash remains tight.
Persistent UnprofitabilityOngoing negative net profit and EBIT margins show the business is not yet operationally self-sustaining. For a drug developer this means continued need for capital to reach commercialization, pressure on management to improve operating efficiency, and potential reprioritization of programs if losses persist.
Negative Return On EquityNegative ROE signals the company is not generating returns on shareholder capital, undermining long-term investor value creation. Over a multi-month horizon this may force management to alter strategy, seek dilutive financing, or pursue asset sales/partnering to rectify capital inefficiency and restore investor confidence.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $1.13 and its highest was $3.90 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $5.69M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is May 13, 2026 which is in 71 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Nov 11, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.06.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 4,905,945 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went up 1.744%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma (SBFM) is a biopharmaceutical company focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the biotechnology sector, where it specializes in drug discovery and development, particularly in the areas of oncology and related treatments. Sunshine Biopharma's core products include a pipeline of drug candidates that address unmet medical needs, leveraging advanced technologies to enhance therapeutic efficacy and patient outcomes.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---